Ekspresija E-selektina u mišjem sjemeniku nakon njegove pokusne torzije (ishemije/reperfuzije).

Germ cell-specific apoptosis occurs after ischemia/reperfusion of the testis and is dependent on E-selectin expression. The aim of the study was to determine differences in E-selectin expression in testes tissues of control, sham and treatment groups after ischemia/reperfusion in mice. Mice were subjected to 720° testicular torsion for 1 h or 2 h duration (ischemia) followed by detorsion (reperfusion). After 2 h of reperfusion, the testes were fixed in Bouin fixative and immunohistochemical analysis performed for E-Selectin expression. E-selectin expression increased in the ischemic testis and contralateral testis after 2 h of reperfusion in mice. This increase in E-selectin expression may confirm that E-selectins play a key role in mediating of apoptosis in germ cells after ischemia/reperfusion. Thus, the blockage of E-selectins might be a strategy for rescue of post-ischemic testes.Apoptoza germinativnih stanica javlja se nakon ishemije i reperfuzije sjemenika, a ovisna je o ekspresiji E-selektina. Cilj ovog istraživanja bio je odrediti razlike u ekspresiji E-selektina u tkivu sjemenika kontrolne, placebo i pokusne skupine nakon ishemije/reperfuzije u miševa. Miševi su bili podvrgnuti torziji sjemenika od 7200 tijekom jednog ili dva sata (ishemija), nakon čega je slijedila detorzija (reperfuzija). Nakon dva sata reperfuzije tkivo sjemenika bilo je fiksirano u Bouinovom fiksativu i pretraženo imunohistokemijski na ekspresiju E-selektina. Ekspresija E-selektina povećala se u ishemičnih sjemenika nakon dva sata reperfuzije. Može se reći da povećanje ekspresije E-selektina potvrđuje njhovu ključnu ulogu u nastanku apoptoze germinativnih stanica nakon ishemije/reperfuzije pa bi blokada E-selektina mogla biti od važnosti za spašavanje sjemenika nakon ishemije

Effect of timing of frozen semen insemination on pregnancy rate in mares

vo

Using Dynamic Maneuvers in the Computed Tomography/Magnetic Resonance Assessment of Lesions of the Head and Neck

WOS: 000327691500012PubMed ID: 23267522Despite advances in technology, the radiologic assessment of certain head and neck lesions may still pose difficulties because of the complex anatomy of this region, the small and mobile structures that this region harbors, and the apposition of mucosal surfaces in the neutral position. Certain maneuvers have been described in the literature to overcome these difficulties. We review the use of the Valsalva and the modified Valsalva maneuver, the puffed-cheek technique, phonation, and inspiration, with possible applications in head and neck imaging

Efficiency of Magnetic Resonance Imaging in Regional Diagnosis and Classification of Advanced Chondropathies of Knee Joint

Objective: Today, magnetic resonance imaging (MRI) procedures used to detect and measure articular hyaline cartilaginous defects are being increasingly investigated. In this study, we evaluated the sensitivity and diagnostic efficiency of MRI in the detection of particularly advanced cartilage pathologies compared to the arthroscopic results

Dynamic Computed Tomographic Evaluation of Vocal Cord Mobility in Patients With Larynx Cancer

Objective: To evaluate the accuracy of dynamic laryngeal computed tomography (DLCT) for the detection of vocal cord mobility in larynx cancer

Association of Iliotibial Band Friction Syndrome with Patellar Height and Facets Variations: A Magnetic Resonance Imaging Study

Objectives: The aim of the study was to evaluate magnetic resonance imaging (MRI) findings of iliotibial band friction syndrome (ITBFS) and its association with patellar height and facet shape variations

Regional distribution of genetic mutation in lung cancer in Turkey (REDIGMA)

Introduction: The results of standard chemotherapy in lung cancer are not very satisfactory, so it is important to identify genetic mutations that provide targeted therapies. Recent reports have suggested influences of racial difference on the frequency of mutation in lung cancer. We aimed to determine the frequency and regional distribution of genetic mutations of non-small cell lung cancer (NSCLC) in Turkey

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and >= 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET